Windtree Therapeutics Stock Performance
| WINT Stock | USD 1.73 0.25 16.89% |
The firm maintains a market beta of -0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Windtree Therapeutics are expected to decrease at a much lower rate. During the bear market, Windtree Therapeutics is likely to outperform the market. At this point, Windtree Therapeutics has a negative expected return of -2.69%. Please make sure to check out Windtree Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Windtree Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Windtree Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:18 | Dividend Date 2020-04-29 | Last Split Date 2024-04-22 |
1 | Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the ... | 01/15/2025 |
2 | Disposition of 275938 shares by Huang James of Windtree Therapeutics at 12.09 subject to Rule 16b-3 | 01/23/2025 |
3 | Windtree Therapeutics adjusts Series C Preferred Stock terms - Investing.com | 01/27/2025 |
4 | Windtree Therapeutics Holds Special Meeting of Stockholders, Receives Approval for Amendments A Look Inside the 8-K Filing | 02/04/2025 |
5 | Disposition of 334 shares by Craig Fraser of Windtree Therapeutics subject to Rule 16b-3 | 02/19/2025 |
6 | Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India - Yahoo Finance | 02/27/2025 |
7 | Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.57 subject to Rule 16b-3 | 02/28/2025 |
8 | Windtree Therapeutics Shares Are Volatile Whats Going On | 03/04/2025 |
9 | Acquisition by Craig Fraser of 68800 shares of Windtree Therapeutics at 1.21 subject to Rule 16b-3 | 03/07/2025 |
10 | Cardiogenic Shock Market Report 2025 North America Europe Lead Cardiogenic Shock Market as Demand for ECMO pVADs Surges | 03/13/2025 |
11 | Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech ... | 03/20/2025 |
| Begin Period Cash Flow | 6.3 M | |
| Free Cash Flow | -13.5 M |
Windtree |
Windtree Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,500 in Windtree Therapeutics on December 24, 2024 and sell it today you would lose (1,298) from holding Windtree Therapeutics or give up 86.53% of portfolio value over 90 days. Windtree Therapeutics is currently does not generate positive expected returns and assumes 10.5781% risk (volatility on return distribution) over the 90 days horizon. In different words, 94% of stocks are less volatile than Windtree, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Windtree Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Windtree Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Windtree Therapeutics, and traders can use it to determine the average amount a Windtree Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.254
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | WINT |
Estimated Market Risk
| 10.58 actual daily | 94 94% of assets are less volatile |
Expected Return
| -2.69 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Windtree Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Windtree Therapeutics by adding Windtree Therapeutics to a well-diversified portfolio.
Windtree Therapeutics Fundamentals Growth
Windtree Stock prices reflect investors' perceptions of the future prospects and financial health of Windtree Therapeutics, and Windtree Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Windtree Stock performance.
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 822.02 K | ||||
| Shares Outstanding | 8.75 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (20.16 M) | ||||
| Net Income | (20.29 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 16.83 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 5.90 X | ||||
| Cash Flow From Operations | (13.44 M) | ||||
| Earnings Per Share | (19.03) X | ||||
| Market Capitalization | 4.92 M | ||||
| Total Asset | 32.41 M | ||||
| Retained Earnings | (844.82 M) | ||||
| Working Capital | 1.38 M | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
About Windtree Therapeutics Performance
Assessing Windtree Therapeutics' fundamental ratios provides investors with valuable insights into Windtree Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Windtree Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.32 | 3.15 | |
| Return On Tangible Assets | (3.26) | (3.42) | |
| Return On Capital Employed | (0.56) | (0.58) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (6.88) | (6.54) |
Things to note about Windtree Therapeutics performance evaluation
Checking the ongoing alerts about Windtree Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Windtree Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Windtree Therapeutics generated a negative expected return over the last 90 days | |
| Windtree Therapeutics has high historical volatility and very poor performance | |
| Windtree Therapeutics may become a speculative penny stock | |
| Windtree Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (20.29 M) with loss before overhead, payroll, taxes, and interest of (17.79 M). | |
| Windtree Therapeutics currently holds about 11.38 M in cash with (13.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37. | |
| Windtree Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech ... |
- Analyzing Windtree Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Windtree Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Windtree Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Windtree Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Windtree Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Windtree Therapeutics' stock. These opinions can provide insight into Windtree Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.